[go: up one dir, main page]

AR127064A1 - Prodroga de derivados de pirrolidona como activador de glucoquinasa - Google Patents

Prodroga de derivados de pirrolidona como activador de glucoquinasa

Info

Publication number
AR127064A1
AR127064A1 ARP220102495A ARP220102495A AR127064A1 AR 127064 A1 AR127064 A1 AR 127064A1 AR P220102495 A ARP220102495 A AR P220102495A AR P220102495 A ARP220102495 A AR P220102495A AR 127064 A1 AR127064 A1 AR 127064A1
Authority
AR
Argentina
Prior art keywords
prodrugs
glucokinase activator
compound
formula
pyrrolidone derivatives
Prior art date
Application number
ARP220102495A
Other languages
English (en)
Inventor
Fuxing Tang
Jin She
Li Chen
Guanghua Lv
Xiangle Jin
Original Assignee
Hua Medicine Shanghai Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hua Medicine Shanghai Ltd filed Critical Hua Medicine Shanghai Ltd
Publication of AR127064A1 publication Critical patent/AR127064A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente descripción proporciona un compuesto de la fórmula (1), o un producto isotópicamente marcado, un enantiómero, un diastereómero o una sal farmacéuticamente aceptable de los mismos; una composición farmacéutica que comprende un compuesto de la fórmula (1); y el uso de un compuesto de la fórmula (1) o una composición farmacéutica del mismo en el tratamiento de diabetes mellitus y síntomas relacionados.
ARP220102495A 2021-09-15 2022-09-14 Prodroga de derivados de pirrolidona como activador de glucoquinasa AR127064A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111079620 2021-09-15
CN202211093895 2022-09-08

Publications (1)

Publication Number Publication Date
AR127064A1 true AR127064A1 (es) 2023-12-13

Family

ID=83505858

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102495A AR127064A1 (es) 2021-09-15 2022-09-14 Prodroga de derivados de pirrolidona como activador de glucoquinasa

Country Status (18)

Country Link
US (2) US12054477B2 (es)
EP (1) EP4244221B1 (es)
JP (1) JP7751731B2 (es)
KR (1) KR20240044465A (es)
CN (1) CN117940419A (es)
AR (1) AR127064A1 (es)
AU (1) AU2022346020A1 (es)
CA (1) CA3231566A1 (es)
CL (1) CL2024000738A1 (es)
CO (1) CO2024002748A2 (es)
EC (1) ECSP24020925A (es)
GE (1) GEAP202416483A (es)
IL (1) IL311237A (es)
MX (1) MX2024003068A (es)
PE (1) PE20240933A1 (es)
TW (1) TW202328107A (es)
WO (1) WO2023040937A1 (es)
ZA (1) ZA202402086B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020451966A1 (en) * 2020-06-04 2023-01-19 Hua Medicine (Shanghai) Ltd. Glucokinase activator for treating diabetes with hepatic impairment
AR132113A1 (es) * 2023-03-13 2025-05-28 Hua Medicine Shanghai Ltd Forma sólida de derivados de pirrolidona como activador de glucoquinasa
WO2024251159A1 (zh) 2023-06-06 2024-12-12 华领医药技术（上海）有限公司 用于认知障碍和神经退行性疾病的葡萄糖激酶激活剂
US20250195440A1 (en) 2023-12-14 2025-06-19 Hua Medicine USA Inc. Pharmaceutical formulation comprising glucokinase activator and use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710205B2 (en) 2000-02-22 2004-03-23 Ono Pharmaceutical Co., Ltd. Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
WO2009126782A1 (en) 2008-04-11 2009-10-15 High Point Pharmaceuticals, Llc Histamine h3 receptor ligands
EP2276479B1 (en) 2008-04-15 2014-07-02 SineVir Therapeutics LLC Prodrugs of neuraminidase inhibitors
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US8258134B2 (en) * 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
CA2740193A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US8772541B2 (en) 2011-12-15 2014-07-08 University of Pittsburgh—of the Commonwealth System of Higher Education Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases
BR112015015229B1 (pt) 2012-12-25 2020-07-07 Hua Medicine processo para a preparação de um composto da fórmula, e, composto
EP3317273B1 (en) 2015-06-30 2021-12-29 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
US20180305334A1 (en) 2015-10-14 2018-10-25 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
PL3556354T3 (pl) 2016-12-15 2025-11-03 Hua Medicine (Shanghai) Ltd. Doustny preparat aktywatora glukokinazy i sposób jego wytwarzania
KR20200011426A (ko) 2017-04-20 2020-02-03 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 K-ras 조절인자
CN110548147B (zh) * 2018-05-31 2022-01-14 华领医药技术（上海）有限公司 含有葡萄糖激酶激活剂和dpp-iv抑制剂的药物组合及其制备方法和用途
TW202043198A (zh) 2019-01-17 2020-12-01 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關之病況的化合物及組合物
US10689360B1 (en) 2019-01-30 2020-06-23 Insilico Medicine Ip Limited TLR inhibitors
US11008303B2 (en) 2019-01-30 2021-05-18 Insilico Medicine Ip Limited TLR 9 inhibitors
WO2022040604A1 (en) 2020-08-21 2022-02-24 BioAge Labs, Inc. Use of dp1 receptor antagonists for the treatment of viral respiratory tract infections and dysregulated immune response in aged and aging patients

Also Published As

Publication number Publication date
KR20240044465A (ko) 2024-04-04
IL311237A (en) 2024-05-01
TW202328107A (zh) 2023-07-16
GEAP202416483A (en) 2024-04-25
WO2023040937A1 (en) 2023-03-23
JP7751731B2 (ja) 2025-10-08
EP4244221A1 (en) 2023-09-20
US20240336597A1 (en) 2024-10-10
CO2024002748A2 (es) 2024-03-27
CA3231566A1 (en) 2023-03-23
CN117940419A (zh) 2024-04-26
US20230322738A1 (en) 2023-10-12
EP4244221B1 (en) 2025-12-10
CL2024000738A1 (es) 2024-08-30
ZA202402086B (en) 2024-11-27
US12054477B2 (en) 2024-08-06
PE20240933A1 (es) 2024-04-30
JP2024533536A (ja) 2024-09-12
ECSP24020925A (es) 2024-04-30
AU2022346020A1 (en) 2024-03-21
MX2024003068A (es) 2024-03-27

Similar Documents

Publication Publication Date Title
AR127064A1 (es) Prodroga de derivados de pirrolidona como activador de glucoquinasa
CO2022016323A2 (es) Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica que constituye el mismo
AR051405A1 (es) Compuestos de 2-carboxamido(3-amino)tiofeno
AR079208A2 (es) Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica
CL2009000780A1 (es) Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k.
CL2010001358A1 (es) Composicion farmaceutica que comprende un vehiculo farmaceuticamente aceptable y una combinacion de dos dosis de pramipexol y rasagilina, en donde la combinacion a dosis fija contiene desde 0,06 a menos de 1,5 mg de pramipexol y desde 0,05 mg a menos de 1,0 mg de rasagilina.
UY27518A1 (es) Nuevos derivados de pirrolidina
CL2011001027A1 (es) Compuestos derivados de 1-(benzo[d][1,3]dioxol-6-il]-n(1h-indol-5-il)ciclopropano carboxamida; moduladores abc; composicion farmaceutica que los comprende; metodo in vitro de incremento de transportadores abc; kit farmaceutico; y su uso en el tratamiento de fibrosis quisticas, problemas metabolicos, del snc, entre otros.
ECSP066302A (es) Omega-carboxiaril-difenil-urea sustituida con flúor para el tratamiento y la prevención de enfermedades y afecciones
AR059948A1 (es) Formas farmaceuticas y metodos de tratamiento que usan un inhibidor de la tirosinacinasa
DOP2009000124A (es) Derivados de benzamida como receptores agonista ep4
AR047070A1 (es) Derivados de difenilazetidona
AR077464A1 (es) Terapia de combinacion para el tratamiento de la diabetes
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
CO6640335A2 (es) Tratamiento terapéutico para síndrome metabólico, diabetes de tipo 2, obesidad o prediabetes
AR112284A1 (es) Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico
AR035651A1 (es) Uso de derivados de indol para la manufactura de un medicamento para reducir la presion intraocular y una composicion
AR024998A1 (es) Nuevos retinoides para el tratamiento del enfisema
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
AR128066A1 (es) Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos
MX2024003028A (es) Derivados de 6 aza quinolina y usos relacionados.
UY25800A1 (es) Procedimiento para preparar composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina.
AR056014A1 (es) Compuesto 3-aminocarbazol, composicion farmaceutica que lo contiene y procedimiento para la preparacion del mismo
AR114418A1 (es) Compuesto cíclico de metilactama y su utilización farmacéutica
CR10210A (es) Derivados de benzoisoindol para el tratamiento del dolor